GSC The List

Post Reply

[email protected]
Site Owner
Posts: 1174

Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. (full – 2013)

Cannabis and psychosis: what causes what? (full – 2013)

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission

Associated with Olanzapine-Induced Weight Gain (full – 2013)

An investigation into "two hit" effects of BDNF deficiency and young-adult cannabinoid

receptor stimulation on prepulse inhibition regulation and memory in mice (full – 2013)

The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study (full – 2013)

Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes (full – 2013)

“Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report (full – 2013)

Neuregulin-1 Impairs the Long-term Depression of Hippocampal Inhibitory Synapses by Facilitating the Degradation of Endocannabinoid 2-AG (full – 2013)

Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. (full – 2013)

What does a mouse tell us about neuregulin 1-cannabis interactions? (full – 2013)

Creativity in cannabis-users and in drug addicts in maintenance treatment and in rehabilitation. (abst – 2013)

CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia (abst – 2013)

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats (abst – 2013)

Neonatal lipopolysaccharide treatment has long term effects on monoaminergic and cannabinoid receptors in the rat (abst – 2013)

Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults (abst – 2013)

Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use (abst – 2013)

Neonatal lipopolysaccharide treatment has long-term effects on monoaminergic and cannabinoid receptors in the rat (abst – 2013)

Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse: A Case Report (abst – 2013)

Peripheral endocannabinoid system dysregulation in first-episode psychosis (abst – 2013)

Quantification of endocannabinoids in postmortem brain of schizophrenic subjects (abst – 2013)

Association of Single-Nucleotide Polymorphisms in the Cannabinoid Receptor 2 Gene with Schizophrenia in the Han Chinese Population (abst – 2013)

Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: A time series analysis (abst – 2013)

Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study (abst – 2013)

Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression (abst – 2013)

The role of cannabinoid 1 receptor expressing interneurons in behavior (abst – 2013)

Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders (abst – 2013)

The endocannabinoid system and its possible role in neurobiology of psychiatric disorders (abst – 2013)

Cannabidiol as a potential treatment for psychosis (abst – 2013)

High K2 use rate among psych unit patients (news – 2013)

GABA deficits disturb endocannabinoid system (news – 2013)

Cannabis psychosis admissions rose after drug reclassified to Class B (news – 2013)

Harvard: Marijuana Doesn’t Cause Schizophrenia (news – 2013)

Can The Cannabis Component Cannabidiol (CBD) Cure Schizophrenia? (news – 2013)

The vital role of constitutive GPCR activity in the mesolimbic dopamine system (full – 2014)

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (full – 2014)

CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain

neurotensin (full – 2014)

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (full – 2014)

Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders (full – 2014)

Cannabinoids and schizophrenia: therapeutic prospects (abst – 2014)

A controlled family study of cannabis users with and without psychosis (abst – 2014)

Acute administration of Δ9 tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice (abst – 2014)

Impaired Fear Memory Specificity Associated with Deficient Endocannabinoid Dependent Long-Term Plasticity (abst – 2014)

Anandamide attenuates haloperidol-induced vacuous chewing movements in rats (abst – 2014)

Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia (abst – 2014)

Genetic predisposition to schizophrenia associated with increased use of cannabis (abst – 2014)

Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population (abst – 2014)

Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed (abst – 2014)

Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: A brain stimulation reward study (abst – 2014)

Paranoid Personality Disorder in the United States: The Role of Race, Illicit Drug Use, and Income (abst – 2014)

Cannabis use and suicidal ideations in high-school students (abst – 2014)

Cannabinoid Transmission in the Prefrontal Cortex Bi-Phasically Controls Emotional Memory Formation via Functional Interactions with the Ventral Tegmental Area (abst – 2014)

Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series (abst – 2014)

The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol (abst – 2014)

Hippocampal Cannabinoid Transmission Modulates Dopamine Neuron Activity: Impact on Rewarding Memory Formation and Social Interaction (abst – 2014)

Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia (abst – 2014)

Risk-taking in schizophrenia and controls with and without cannabis dependence (abst – 2014)

Developmentally vitamin D-deficient rats show enhanced prepulse inhibition after acute Δ9-tetrahydrocannabinol. (abst – 2014)

Increasing Endocannabinoid Levels in the Ventral Pallidum Restore Aberrant Dopamine Neuron Activity in the Subchronic PCP Rodent Model of Schizophrenia (abst – 2014)

The phytocannabinoid, Δ9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce anti-psychotic effects (abst – 2014)

Is Medical Marijuana Destined to Become a Top Schizophrenia Treatment? (news – 2014) (requires free registration)

Cannabis conundrum: Evidence of harm?: Opposition to marijuana use is often rooted in arguments about the drug's harm to children and adults, but the scientific evidence is seldom clear-cut (article – 2015)

Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. (abst – 2015)

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects (abst – 2015)

Cannabidiol Attenuates Sensorimotor Gating Disruption and Molecular Changes Induced by Chronic Antagonism of NMDA receptors in Mice (abst – 2015)

Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study (1st page – 2015)

Marijuana Could Be the Answer to Fighting These 3 Diseases (news – 2015) (may require free registration)

March 28, 2015 at 8:06 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.